On Monday, Twist Bioscience received a positive adjustment to its Relative Strength (RS) Rating, from 88 to 91.
This exclusive rating from Investor's Business Daily measures price action with a 1 (worst) to 99 (best) score. The score shows how a stock's price movement over the last 52 weeks stacks up against all the other stocks in our database.
Decades of market research reveals that the market's biggest winners typically have an RS Rating of over 80 at the beginning of a new climb.
How To Use Stock Charts To Stay Profitable And Protected
Twist Bioscience is working on a cup without handle with a 60.90 entry. See if the stock can break out in heavy volume.
Twist Bioscience showed 0% EPS growth in the latest quarterly report. Sales gains came in at 27%.
The company earns the No. 85 rank among its peers in the Medical-Biomed/Biotech industry group. ADMA Biologics, Corcept Therapeutics and Catalyst Pharmaceuticals are among the top 5 highly rated stocks within the group.
RELATED:
Biotech And Pharmaceutical Industry And Stock News
IBD Stock Rating Upgrades: Rising Relative Strength
Why Should You Use IBD's Relative Strength Rating?
How Relative Strength Line Can Help You Judge A Stock
Ready To Grow Your Investing Skills? Join An IBD Meetup Group!
